$45.00
Synergistic GH secretagogue blend combining CJC-1295 (without DAC) and Ipamorelin. Studied for growth hormone stimulation and metabolic research. 5mg | For research and laboratory use only.
CJC-1295 (without DAC) + Ipamorelin is a research peptide blend combining two complementary growth hormone secretagogues. CJC-1295 (without DAC), also known as Mod GRF 1-29, is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist.
When studied together in laboratory settings, these two peptides are believed to act synergistically — CJC-1295 stimulates GHRH receptors to promote GH release, while Ipamorelin mimics ghrelin to selectively trigger additional GH secretion without significantly impacting cortisol or prolactin levels. This combination has become one of the most studied peptide pairings in growth hormone research.
Key Research Features:
– Synergistic GH Stimulation: Studied for the combined effect of GHRH and GHSR activation in laboratory models
– Selective GH Release: Ipamorelin component investigated for targeted GH secretion with minimal hormonal side effects
– Metabolic Research: Explored for effects on body composition, fat metabolism, and energy balance
– Anti-Aging Studies: Associated with research on GH-related aging mechanisms and tissue repair
– Research-Grade Quality: Intended strictly for laboratory and scientific research purposes only
Orders Over $500
CJC-1295 (without DAC) + Ipamorelin is a research peptide blend combining two complementary growth hormone secretagogues. CJC-1295 (without DAC), also known as Mod GRF 1-29, is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist.
When studied together in laboratory settings, these two peptides are believed to act synergistically — CJC-1295 stimulates GHRH receptors to promote GH release, while Ipamorelin mimics ghrelin to selectively trigger additional GH secretion without significantly impacting cortisol or prolactin levels. This combination has become one of the most studied peptide pairings in growth hormone research.
Key Research Features:
– Synergistic GH Stimulation: Studied for the combined effect of GHRH and GHSR activation in laboratory models
– Selective GH Release: Ipamorelin component investigated for targeted GH secretion with minimal hormonal side effects
– Metabolic Research: Explored for effects on body composition, fat metabolism, and energy balance
– Anti-Aging Studies: Associated with research on GH-related aging mechanisms and tissue repair
– Research-Grade Quality: Intended strictly for laboratory and scientific research purposes only
Reviews
There are no reviews yet.